JP2016506418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506418A5 JP2016506418A5 JP2015552757A JP2015552757A JP2016506418A5 JP 2016506418 A5 JP2016506418 A5 JP 2016506418A5 JP 2015552757 A JP2015552757 A JP 2015552757A JP 2015552757 A JP2015552757 A JP 2015552757A JP 2016506418 A5 JP2016506418 A5 JP 2016506418A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- groups
- unsubstituted
- substituted
- pdgfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 238000000034 method Methods 0.000 claims 19
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 108091008606 PDGF receptors Proteins 0.000 claims 8
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 8
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 7
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 7
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 7
- QSZCGGBDNYTQHH-UHFFFAOYSA-N 2,3-dimethoxyphenol Chemical compound COC1=CC=CC(O)=C1OC QSZCGGBDNYTQHH-UHFFFAOYSA-N 0.000 claims 6
- 208000019693 Lung disease Diseases 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 5
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 5
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims 4
- -1 guanidinyl groups Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- JHJNPOSPVGRIAN-SFHVURJKSA-N n-[3-[(1s)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=CC(N[C@@H](C)C=2C=C(NC(=O)C=3C=C(C)C=NC=3)C=CC=2)=N1 JHJNPOSPVGRIAN-SFHVURJKSA-N 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 210000001147 pulmonary artery Anatomy 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims 2
- 102000012085 Endoglin Human genes 0.000 claims 2
- 108010036395 Endoglin Proteins 0.000 claims 2
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 claims 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 210000000651 myofibroblast Anatomy 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 201000006306 Cor pulmonale Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 claims 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 208000021068 Pulmonary arterial hypertension associated with portal hypertension Diseases 0.000 claims 1
- 208000021085 Pulmonary hypertension with unclear multifactorial mechanism Diseases 0.000 claims 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000017304 adult pulmonary Langerhans cell histiocytosis Diseases 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- 230000037147 athletic performance Effects 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 230000009547 development abnormality Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940001447 lactate Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000003492 pulmonary vein Anatomy 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 238000010911 splenectomy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751217P | 2013-01-10 | 2013-01-10 | |
| US61/751,217 | 2013-01-10 | ||
| US201361889887P | 2013-10-11 | 2013-10-11 | |
| US61/889,887 | 2013-10-11 | ||
| PCT/US2014/010778 WO2014110200A1 (en) | 2013-01-10 | 2014-01-09 | Non-selective kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018106185A Division JP6547042B2 (ja) | 2013-01-10 | 2018-06-01 | 非選択的キナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506418A JP2016506418A (ja) | 2016-03-03 |
| JP2016506418A5 true JP2016506418A5 (cg-RX-API-DMAC7.html) | 2016-04-14 |
| JP6387488B2 JP6387488B2 (ja) | 2018-09-12 |
Family
ID=51167358
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552757A Active JP6387488B2 (ja) | 2013-01-10 | 2014-01-09 | 非選択的キナーゼ阻害剤 |
| JP2018106185A Active JP6547042B2 (ja) | 2013-01-10 | 2018-06-01 | 非選択的キナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018106185A Active JP6547042B2 (ja) | 2013-01-10 | 2018-06-01 | 非選択的キナーゼ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9815815B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3007689B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6387488B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105142624A (cg-RX-API-DMAC7.html) |
| AU (5) | AU2014205483B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2897651C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3007689T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2675720T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014110200A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014205483B2 (en) * | 2013-01-10 | 2017-11-30 | Gilead Sciences, Inc. | Non-selective kinase inhibitors |
| US20150352111A1 (en) * | 2013-01-10 | 2015-12-10 | Pulmokine, Inc. | Therapeutic Indications of Kinase Inhibitors |
| AU2014229313B2 (en) | 2013-03-14 | 2016-07-28 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| CA3172586C (en) * | 2013-07-31 | 2025-10-14 | Avalyn Pharma Inc. | IMATINIB AEROSOL COMPOUNDS AND RELATED USES |
| EP3054937B1 (en) * | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Spray dry formulations |
| WO2018081567A1 (en) | 2016-10-27 | 2018-05-03 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
| JP2020514747A (ja) * | 2017-03-16 | 2020-05-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｋｒａｓ陽性癌の診断法及び治療法 |
| WO2019157337A1 (en) * | 2018-02-08 | 2019-08-15 | Pulmokine, Inc. | Formulations of kinase inhibitors and prostanoids |
| CN109574296B (zh) * | 2018-11-27 | 2021-05-07 | 合肥工业大学 | 一种从含蟹肉蛋白废水中回收蛋白的方法 |
| US11464776B2 (en) | 2019-05-16 | 2022-10-11 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
| EP3968963A4 (en) * | 2019-05-16 | 2023-02-01 | Aerovate Therapeutics, Inc. | IMATINIB FORMULATIONS, THEIR PREPARATION AND USES |
| US20240228462A1 (en) | 2021-05-07 | 2024-07-11 | Gb002, Inc. | Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2- yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods |
| JP2024540411A (ja) | 2021-11-08 | 2024-10-31 | プロジェントス・セラピューティクス・インコーポレイテッド | 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用 |
| WO2024035884A1 (en) * | 2022-08-10 | 2024-02-15 | Gb002, Inc. | Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (pah) |
| CN119930631B (zh) * | 2025-04-07 | 2025-06-24 | 山东大学 | 一种靶向ddr1受体的化合物及其衍生的放射性示踪剂 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118401A (en) | 1977-10-19 | 1978-10-03 | American Hoechst Corporation | Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor |
| JPS5488231A (en) | 1977-12-22 | 1979-07-13 | Sumitomo Chem Co Ltd | 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| US5648369A (en) * | 1991-11-20 | 1997-07-15 | University Of Kentucky Research Foundation | Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists |
| BR9610048A (pt) | 1995-08-30 | 1999-07-06 | Bayer Ag | Acil amino salicilamidas |
| JPH09268169A (ja) | 1996-04-01 | 1997-10-14 | Otsuka Chem Co Ltd | サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤 |
| DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| CA2382821A1 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| US6451830B1 (en) | 1999-09-23 | 2002-09-17 | G.D. Searle & Co. | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity |
| EP1226119B1 (en) | 1999-10-19 | 2005-03-16 | MERCK & CO. INC. | Tyrosine kinase inhibitors |
| GEP20053530B (en) | 1999-10-19 | 2005-05-25 | Merck & Co Inc | Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2400923A1 (en) | 2000-02-25 | 2001-08-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2436487A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd. | Methods of inhibiting kinases |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| NZ537156A (en) | 2002-05-23 | 2007-06-29 | Cytopia Pty Ltd | Kinase inhibitors |
| AUPS251502A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Protein kinase inhibitors |
| ATE408583T1 (de) * | 2002-05-23 | 2008-10-15 | Cohen Ben Z | Medizinisch genaues pumpsystem |
| IL165264A0 (en) | 2002-05-23 | 2005-12-18 | Cytopia Pty Ltd | Protein kinase inhibitors |
| DK1522314T3 (da) | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
| WO2004004720A1 (en) | 2002-07-03 | 2004-01-15 | Astex Technology Limited | 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
| CA2492593A1 (en) | 2002-07-15 | 2004-01-22 | Myriad Genetics, Inc. | Compounds, compositions, and methods employing same |
| AU2003272007A1 (en) | 2002-10-25 | 2004-05-13 | The Administrators Of The Tulane Educational Fund | Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
| US20050026879A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| PE20050338A1 (es) | 2003-08-06 | 2005-05-16 | Vertex Pharma | Compuestos de aminotriazoles como inhibidores de proteina quinasas |
| EP2762475A1 (en) | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
| KR101260717B1 (ko) | 2003-12-03 | 2013-05-09 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 튜불린 저해제 |
| PT1689739T (pt) * | 2003-12-03 | 2016-07-13 | Ym Biosciences Australia Pty | Inibidores de cinases baseados em azol |
| JP5283336B2 (ja) | 2004-01-12 | 2013-09-04 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | 選択的キナーゼ阻害剤 |
| WO2005114219A2 (en) | 2004-05-20 | 2005-12-01 | Wyeth | Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases |
| JP2006111553A (ja) | 2004-10-13 | 2006-04-27 | Dainippon Sumitomo Pharma Co Ltd | スルホニルオキシインドール誘導体及びそれを含有する医薬組成物 |
| DK1948176T3 (da) | 2005-11-10 | 2011-04-18 | Bayer Schering Pharma Ag | Diarylurinstoffer til behandling af pulmonær hypertension |
| US20090197922A1 (en) | 2006-01-24 | 2009-08-06 | The University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| AU2007220047B2 (en) * | 2006-02-28 | 2013-08-01 | Ym Biosciences Australia Pty Ltd | Inhibition of JAK2 as a treatment of pulmonary arterial hypertension |
| WO2007124382A2 (en) | 2006-04-19 | 2007-11-01 | Novartis Vaccines And Diagnostics, Inc. | Inhaled imipenem |
| LT2848610T (lt) | 2006-11-15 | 2017-11-10 | Ym Biosciences Australia Pty Ltd | Kinazės aktyvumo inhibitoriai |
| KR101145520B1 (ko) | 2007-05-04 | 2012-05-16 | 노파르티스 아게 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물 |
| CN101687853A (zh) | 2007-05-04 | 2010-03-31 | Irm责任有限公司 | 作为c-kit和pdgfr激酶抑制剂的嘧啶衍生物和组合物 |
| ATE520682T1 (de) | 2007-08-22 | 2011-09-15 | Irm Llc | 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren |
| KR101218926B1 (ko) | 2007-08-22 | 2013-01-04 | 아이알엠 엘엘씨 | 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물 |
| AU2008340733B9 (en) | 2007-12-20 | 2014-03-06 | Ph Pharma Co., Ltd. | 4-(4-Cyano-2-thioaryl)dihydropyrimidinones and use thereof |
| WO2010019540A1 (en) | 2008-08-13 | 2010-02-18 | Novartis Ag | Treatment of pulmonary arterial hypertension |
| DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
| US8685458B2 (en) | 2009-03-05 | 2014-04-01 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
| WO2010132827A1 (en) | 2009-05-15 | 2010-11-18 | Bend Research, Inc. | Low-molecular dextran for powder inhalations |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2012031129A2 (en) | 2010-09-03 | 2012-03-08 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
| EP2618924A1 (en) | 2010-09-24 | 2013-07-31 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| BR112013029803B1 (pt) | 2011-05-19 | 2021-07-13 | Savara, Inc | Composições de vancomicina em pó seco |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EA026152B1 (ru) | 2011-09-01 | 2017-03-31 | Новартис Аг | СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ с-kit |
| US20150352111A1 (en) | 2013-01-10 | 2015-12-10 | Pulmokine, Inc. | Therapeutic Indications of Kinase Inhibitors |
| AU2014205483B2 (en) | 2013-01-10 | 2017-11-30 | Gilead Sciences, Inc. | Non-selective kinase inhibitors |
| CA3172586C (en) | 2013-07-31 | 2025-10-14 | Avalyn Pharma Inc. | IMATINIB AEROSOL COMPOUNDS AND RELATED USES |
| EP3054937B1 (en) | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Spray dry formulations |
| WO2015179369A1 (en) | 2014-05-20 | 2015-11-26 | Infinity Pharmaceuticals, Inc. | Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors |
-
2014
- 2014-01-09 AU AU2014205483A patent/AU2014205483B2/en active Active
- 2014-01-09 EP EP14737648.7A patent/EP3007689B1/en active Active
- 2014-01-09 CA CA2897651A patent/CA2897651C/en active Active
- 2014-01-09 CN CN201480010529.XA patent/CN105142624A/zh active Pending
- 2014-01-09 ES ES14737648.7T patent/ES2675720T3/es active Active
- 2014-01-09 US US14/760,139 patent/US9815815B2/en active Active
- 2014-01-09 JP JP2015552757A patent/JP6387488B2/ja active Active
- 2014-01-09 DK DK14737648.7T patent/DK3007689T3/en active
- 2014-01-09 CN CN201811323814.3A patent/CN109568319A/zh active Pending
- 2014-01-09 WO PCT/US2014/010778 patent/WO2014110200A1/en not_active Ceased
-
2017
- 2017-07-26 US US15/660,551 patent/US10246438B2/en active Active
-
2018
- 2018-02-27 AU AU2018201406A patent/AU2018201406A1/en not_active Abandoned
- 2018-06-01 JP JP2018106185A patent/JP6547042B2/ja active Active
-
2019
- 2019-02-12 US US16/273,878 patent/US10532994B2/en active Active
-
2020
- 2020-12-17 AU AU2020289802A patent/AU2020289802A1/en not_active Abandoned
-
2023
- 2023-03-15 AU AU2023201605A patent/AU2023201605B2/en active Active
-
2024
- 2024-11-04 AU AU2024259702A patent/AU2024259702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506418A5 (cg-RX-API-DMAC7.html) | ||
| JP2019507781A5 (cg-RX-API-DMAC7.html) | ||
| EP3054937B1 (en) | Spray dry formulations | |
| AU2019219818A1 (en) | S1P receptor modulators for treating multiple sclerosis | |
| Forrest | Anaesthesia and right ventricular failure | |
| JP2016506417A5 (cg-RX-API-DMAC7.html) | ||
| JP2014077003A5 (cg-RX-API-DMAC7.html) | ||
| JP2010520306A5 (cg-RX-API-DMAC7.html) | ||
| JP2010520308A5 (cg-RX-API-DMAC7.html) | ||
| MX2009001534A (es) | Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva. | |
| RU2012134510A (ru) | Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников | |
| JP2018168165A5 (cg-RX-API-DMAC7.html) | ||
| FI3258919T4 (fi) | Nasaalinen jauheformulaatio hypoglykemian hoitoon | |
| JP2012528180A5 (cg-RX-API-DMAC7.html) | ||
| JP2014528418A5 (cg-RX-API-DMAC7.html) | ||
| JP5149177B2 (ja) | 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤 | |
| JP2014500280A5 (cg-RX-API-DMAC7.html) | ||
| JP2024175025A (ja) | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 | |
| JP5068253B2 (ja) | 心臓血管疾患の治療 | |
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| CN110845408A (zh) | 同位素富集的乐伐替尼 | |
| CN107428753B (zh) | 用于治疗原发性癌症和癌症转移的小分子 | |
| WO2006082490A1 (en) | Injectable formulations of benzimidazole compounds | |
| CN1116871C (zh) | 含有s－烷基异硫脲鎓衍生物的药物组合物 | |
| JP2015533128A5 (cg-RX-API-DMAC7.html) |